Cargando…

Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation

BACKGROUND: Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Oseni, Ellen A., Blumenthal, Miriam, Izard, Stephanie, Qiu, Michael, Mone, Anjali, Swaminath, Arun, Sultan, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990718/
https://www.ncbi.nlm.nih.gov/pubmed/36895626
http://dx.doi.org/10.14740/jocmr4846
_version_ 1784901993822683136
author Oseni, Ellen A.
Blumenthal, Miriam
Izard, Stephanie
Qiu, Michael
Mone, Anjali
Swaminath, Arun
Sultan, Keith
author_facet Oseni, Ellen A.
Blumenthal, Miriam
Izard, Stephanie
Qiu, Michael
Mone, Anjali
Swaminath, Arun
Sultan, Keith
author_sort Oseni, Ellen A.
collection PubMed
description BACKGROUND: Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of 30- and 90-day hospital readmissions. METHODS: We conducted a review of all adults admitted for an IBD exacerbation from January 1, 2016 to March 1, 2020 within the Northwell Health Care system. Patients with an IBD exacerbation were identified by primary or secondary ICD10 code (K50.xx or K51.xx) and administration of intravenous (IV) solumedrol and/or biologic therapy. Admission documents were reviewed for the terms “marijuana”, “cannabis”, “pot” and “CBD”. RESULTS: A total of 1,021 patient admissions met inclusion criteria, of whom 484 (47.40%) had Crohn’s disease (CD) and 542 (53.09%) were female. Pre-admission cannabis use was reported by 74 (7.25%) patients. Factors found to be associated with cannabis use included younger age, male gender, African American/Black race, current tobacco and former alcohol use, anxiety, and depression. Cannabis use was found to be associated with 30-day readmission among patients with ulcerative colitis (UC), but not among patients with CD, after respectively adjusting each final model by other factors (odds ratio (OR): 2.48, 95% confidence interval (CI): 1.06 - 5.79 and OR: 0.59, 95% CI: 0.22 - 1.62, respectively). Cannabis use was not found to be associated with 90-day readmission on univariable analysis (OR: 1.11, 95% CI: 0.65 - 1.87) nor in the final multivariable model after adjusting for other factors (OR: 1.19, 95% CI: 0.68 - 2.05). CONCLUSION: Pre-admission cannabis use was found to be associated with 30-day readmission among patients with UC, but not with 30-day readmission for patients with CD nor with 90-day readmission, following an IBD exacerbation.
format Online
Article
Text
id pubmed-9990718
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-99907182023-03-08 Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation Oseni, Ellen A. Blumenthal, Miriam Izard, Stephanie Qiu, Michael Mone, Anjali Swaminath, Arun Sultan, Keith J Clin Med Res Original Article BACKGROUND: Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of 30- and 90-day hospital readmissions. METHODS: We conducted a review of all adults admitted for an IBD exacerbation from January 1, 2016 to March 1, 2020 within the Northwell Health Care system. Patients with an IBD exacerbation were identified by primary or secondary ICD10 code (K50.xx or K51.xx) and administration of intravenous (IV) solumedrol and/or biologic therapy. Admission documents were reviewed for the terms “marijuana”, “cannabis”, “pot” and “CBD”. RESULTS: A total of 1,021 patient admissions met inclusion criteria, of whom 484 (47.40%) had Crohn’s disease (CD) and 542 (53.09%) were female. Pre-admission cannabis use was reported by 74 (7.25%) patients. Factors found to be associated with cannabis use included younger age, male gender, African American/Black race, current tobacco and former alcohol use, anxiety, and depression. Cannabis use was found to be associated with 30-day readmission among patients with ulcerative colitis (UC), but not among patients with CD, after respectively adjusting each final model by other factors (odds ratio (OR): 2.48, 95% confidence interval (CI): 1.06 - 5.79 and OR: 0.59, 95% CI: 0.22 - 1.62, respectively). Cannabis use was not found to be associated with 90-day readmission on univariable analysis (OR: 1.11, 95% CI: 0.65 - 1.87) nor in the final multivariable model after adjusting for other factors (OR: 1.19, 95% CI: 0.68 - 2.05). CONCLUSION: Pre-admission cannabis use was found to be associated with 30-day readmission among patients with UC, but not with 30-day readmission for patients with CD nor with 90-day readmission, following an IBD exacerbation. Elmer Press 2023-02 2023-02-28 /pmc/articles/PMC9990718/ /pubmed/36895626 http://dx.doi.org/10.14740/jocmr4846 Text en Copyright 2023, Oseni et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Oseni, Ellen A.
Blumenthal, Miriam
Izard, Stephanie
Qiu, Michael
Mone, Anjali
Swaminath, Arun
Sultan, Keith
Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
title Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
title_full Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
title_fullStr Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
title_full_unstemmed Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
title_short Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
title_sort cannabis use and its association with thirty- and ninety-day hospital readmissions for patients admitted for an inflammatory bowel disease exacerbation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990718/
https://www.ncbi.nlm.nih.gov/pubmed/36895626
http://dx.doi.org/10.14740/jocmr4846
work_keys_str_mv AT oseniellena cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation
AT blumenthalmiriam cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation
AT izardstephanie cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation
AT qiumichael cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation
AT moneanjali cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation
AT swaminatharun cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation
AT sultankeith cannabisuseanditsassociationwiththirtyandninetydayhospitalreadmissionsforpatientsadmittedforaninflammatoryboweldiseaseexacerbation